Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.74 |
| ▸ | LTA4H | P09960 | 7/20 | 0.61 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.61 |
| ▸ | BAX | Q07812 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 2/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3845620 | 0.86 | LTA4H (0.50) | MEN1KMT2AESR1ESR2LTA4H | |
| SCHEMBL3841043 | 0.86 | LTA4H (0.50) | MEN1KMT2AESR1ESR2LTA4H | |
| SCHEMBL2883028 | 0.86 | LTA4H (0.50) | MEN1KMT2AESR1ESR2LTA4H | |
| SCHEMBL7811939 | 0.86 | ESR2 (1.00) | MEN1KMT2AESR1ESR2LTA4H | |
| SCHEMBL3175106 | 0.86 | ESR2 (1.00) | MEN1KMT2AESR1ESR2LTA4H | |
| SCHEMBL18198 | 0.86 | ESR2 (1.00) | MEN1KMT2AESR1ESR2LTA4H | |
| SCHEMBL249169 | 0.86 | ESR2 (1.00) | MEN1KMT2AESR1ESR2LTA4H | |
| SCHEMBL24414010 | 0.83 | MEN1 (0.64) | MEN1KMT2AESR1ESR2LTA4H | |
| SCHEMBL24413544 | 0.83 | MEN1 (0.50) | MEN1KMT2AESR1ESR2LTA4H | |
| Hydrogen Sulfide SCHEMBL27529439 | 0.83 | MEN1 (0.93) | MEN1KMT2AESR1ESR2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220146930-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-7119201-B2 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1501515-B1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1501515-A1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040006057-A1 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER PRODUCTS INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003090752-A1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-4638099-A | Method for making 4,4'-dihydroxydiphenyl ether | ROHM GMBH (DE) | 1987-01-20 | — | — | US | disclosed |
| US-4638099-A | Method for making 4,4'-dihydroxydiphenyl ether | ROHM GMBH (DE) | 1987-01-20 | — | — | US | disclosed |
| US-4365991-A | HERBICIDES | HOFFMANN-LA ROCHE INC. (US) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006057-A1 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP8, MMP9, MMP1 | MEN1 4607/4885KMT2A 2274/4885ESR1 1606/4885 |
| US-20220146930-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | RER1, FGFR1, NHERF1 | MEN1 2209/4885KMT2A 1914/4885ESR1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.